Sierra Legacy Group Buys 590 Shares of Icon Plc $ICLR

Sierra Legacy Group boosted its stake in shares of Icon Plc (NASDAQ:ICLR) by 15.4% in the 2nd quarter, Holdings Channel.com reports. The firm owned 4,430 shares of the medical research company’s stock after buying an additional 590 shares during the quarter. Sierra Legacy Group’s holdings in Icon were worth $644,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. SVB Wealth LLC acquired a new position in shares of Icon during the first quarter valued at about $28,000. Ameritas Advisory Services LLC acquired a new position in Icon in the 2nd quarter valued at approximately $48,000. LRI Investments LLC acquired a new position in Icon in the 2nd quarter valued at approximately $49,000. Blue Trust Inc. grew its holdings in shares of Icon by 44.0% during the 2nd quarter. Blue Trust Inc. now owns 393 shares of the medical research company’s stock worth $57,000 after purchasing an additional 120 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Icon by 40,800.0% during the second quarter. Caitong International Asset Management Co. Ltd now owns 409 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 408 shares during the period. 95.61% of the stock is currently owned by institutional investors and hedge funds.

Icon Stock Performance

NASDAQ:ICLR opened at $161.02 on Wednesday. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $13.00 billion, a P/E ratio of 21.79, a price-to-earnings-growth ratio of 3.04 and a beta of 1.22. The firm has a 50 day moving average of $174.92 and a 200-day moving average of $161.15. Icon Plc has a 1 year low of $125.10 and a 1 year high of $228.29.

Icon (NASDAQ:ICLR) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $3.31 earnings per share for the quarter, beating analysts’ consensus estimates of $3.28 by $0.03. The company had revenue of $2.04 billion during the quarter, compared to analyst estimates of $1.98 billion. Icon had a return on equity of 10.58% and a net margin of 7.40%.The firm’s quarterly revenue was up .6% compared to the same quarter last year. During the same period last year, the company posted $3.35 earnings per share. As a group, sell-side analysts anticipate that Icon Plc will post 13.38 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the company. Cowen reaffirmed a “hold” rating on shares of Icon in a research report on Friday, October 24th. Baird R W upgraded shares of Icon from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 24th. Jefferies Financial Group lowered shares of Icon from a “buy” rating to a “hold” rating and dropped their price target for the stock from $220.00 to $175.00 in a research report on Tuesday, September 9th. Rothschild & Co Redburn raised Icon from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $184.00 to $236.00 in a report on Wednesday, September 3rd. Finally, Leerink Partners set a $220.00 price objective on Icon in a research note on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $205.00.

Icon Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.